Advertisement
News
Advertisement

Soligenix Announces Publication of Positive Data Describing Protection from Mucosal and Systemic Ricin Intoxication by Intradermal RiVaxâ„¢ Administration

Fri, 06/25/2010 - 5:34am
Bio-Medicine.Org

PRINCETON, N.J., June 25 /PRNewswire-FirstCall/ -- Soligenix, Inc. (OTC Bulletin Board: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company, announced today the publication of an article in the June 2010 edition of Vaccine, which describes protection from mucosal and systemic ricin intoxication by intradermal administration of RiVax™, the Company's vaccine against ricin toxin. The article was authored by the Company's collaborators at the University of Texas Southwestern Medical Center at Dallas (UT Southwestern) where the vaccine originated. RiVax™ is currently being evaluated in Phase 1 human safety and immunogenicity trials, as well as non-human primate trials for efficacy.

The purpose of this study was to determine whether RiVax™ administered by intradermal (ID) injection would be more immunogenic and protective at lower doses. ID vaccination has several practical advantages in protecting humans due to the ease of administration, especially when using an ID gun, thereby eliminating the need for needles and subsequent needle disposal. In this publication, a comparison of ID and intramuscular (IM) vaccination with or without an aluminum salt adjuvant at several dose levels was investigated. The levels of anti-RiVax™ antibodies generated in serum as well as the ability of the vaccine to protect mice against ricin intoxication following systemic, gastric gavage or aerosol challenges were determined.

The major findings to emerge from this study are as follows:

  1. ID vs. IM administration of RiVax™ without adjuvant conferred equal protection;
  2. RiVax™ adsorbed to aluminum adjuvant was significantly better than RiVax™ alone in eliciting speci

    '/>"/>

SOURCE

Topics

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading